University of Southampton

Sean Lim

Martin John Glennie

Mark Steven Cragg

Peter David Johnson

Björn Frendéus

Ingrid Teige

Stephen Beers

Ali Roghanian

Aymen Al-shamkhani

Bjoern Frendeus

Björn Frendeus

The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.

Cancer and B-cell related disease therapy

The invention provides a method of treating a patient having target cells that express Fc&#x3b3;RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc&#x3b3;RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc&#x3b3;RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc&#x3b3;RIIb.

Combined use of Fc&#x3b3;RIIb (CD32B) and CD20 specific antibodies

The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.

Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies

Growing community of inventors

Southampton, United Kingdom

Sean Lim